Human Monoclonal Antibodies
Human Monoclonal Antibodies
批准号:
8065425
负责人:
Patrick Christopher Wilson
金额:
$58.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
未结题
起止时间:
2003-09-30 至
关键词:
AcuteAddressAdmission activityAdverse eventAffinityAgonistAnthrax VaccinesAntibodiesAntibody FormationAntibody SpecificityAntibody-Dependent EnhancementAntigensAwardB cell differentiationB cell repertoireB-Cell ActivationB-Cell DevelopmentB-LymphocytesBindingBiological AssayBiological WarfareBiologyBloodBlood VesselsBlood specimenCell SeparationCell physiologyCellsChicagoChildClinicalClinical TrialsClonalityCloningCollaborationsCommunicable DiseasesComplement component C1sConvalescenceCross-Sectional StudiesDataDengueDengue Hemorrhagic FeverDengue Shock SyndromeDengue VirusDevelopmentDiagnosisDiagnosticEmerging Communicable DiseasesEpitopesEquilibriumEvaluationEventFc ReceptorFlavivirusFlow CytometryFreezingFundingFutureGenerationsGenesGenus CapraGoalsHospitalsHumanHumoral ImmunitiesImmuneImmune responseImmune systemImmunityImmunoglobulin GImmunoglobulin GenesImmunoglobulin MImmunoglobulin Somatic HypermutationImmunologyIn VitroIncidenceIndividualInfectionInfectious AgentKineticsLaboratoriesLeadLearningLibrariesLifeLinkLiteratureLongitudinal StudiesMemoryMemory B-LymphocyteMethodsModelingMolecularMonoclonal AntibodiesMusPassive ImmunizationPathologyPharmacologic SubstancePhenotypePlasma CellsPlasmablastPopulationProcessProductionProtocols documentationPublic HealthReactionReagentRecording of previous eventsRelianceResearch InfrastructureReverse Transcriptase Polymerase Chain ReactionRoleSamplingSecondary ImmunizationSerologic testsSerologicalSerotypingSerumSeverity of illnessShippingShipsSomatic MutationSorting - Cell MovementSourceSpecificitySpecimenStagingStructure of germinal center of lymph nodeSurveysSymptomsSyndromeTechnologyTestingThailandTherapeuticTimeUniversitiesVaccinatedVaccinationVaccine AntigenVaccinesViralViremiaVirusVirus DiseasesYellow FeverYellow fever virusanthrax toxinbiodefensedesignenzyme linked immunospot assayfascinatehuman monoclonal antibodieshumanized antibodyin vivoinfluenzaviruslong term memorylongitudinal analysismonocytemouse modelneutralizing antibodynew technologynonhuman primatenovelpathogenreceptorrepositoryresponsesecondary infectiontechnology developmenttoolvolunteer
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The isolation of antibodies directly from immune donors offers the advantage of fully exploiting the strength
of the human antibody response to vaccination or infection. By following the developmental fate of antigenspecific
B cell populations through analysis of their antibodies we can generate a direct survey of B cell
function. In this competitive renewal of our Technology Development Project (TOP) on Human Monoclonal
Antibodies we combine two uniquely powerful new technologies recently developed that for the first time
allow the efficient analysis of human B cell specificity en mass. One approach pioneered by Dr.
Lanzavecchia, provides an analysis of the entire history of B cell specificities by efficiently producing mAbs
from the long-term memory B cell compartment. The second technology from the Wilson and Ahmed
laboratories scrutinizes current, ongoing plasmablast specificities and generates large numbers of antigenspecific
antibodies in a short time that are predominantly specific to the antigens. We will use these tools to
address fundamental questions about the human B cell response to yellow fever virus (YFV) and dengue
virus. By combining these powerful platforms of generating human mAbs (plasmablasts and memory B cells)
we should be able to comprehensively analyze the human B cell response to these viruses and to probe the
relationship between memory B cells and antibody secreting plasma cells.
Because the antibodies produced are fully human they can yield valuable diagnostics and allow for safer
Pharmaceuticals than chimeric or humanized antibodies. Thus, in addition to addressing these fundamental
questions, our proposed studies should also result in the development of a large panel of human mAbs
against YFV and dengue - two flaviviruses that are of important public health concern and are high priority
biodefense pathogens. Three specific aims are proposed: 1) Characterize the primary human B cell
response to YFV-17D leading to the generation of ASCs and long-term memory B cells; 2) Analyze the
dynamics, variable gene repertoire, and the specificity of ASC and memory cells induced by booster
vaccination with YFV-17D. 3) Characterize the human B cell response to acute dengue virus infection of
Children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploring the mechanistic basis for altered peripheral B cell selection in SLE
-
批准号:8732775
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2014
-
负责人:Patrick Christopher Wilson
-
依托单位:
Monoclonal Antibody Technology Core
-
批准号:10468074
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2012
-
负责人:Patrick Christopher Wilson
-
依托单位:
Monoclonal Antibody Technology Core
-
批准号:10223126
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2012
-
负责人:Patrick Christopher Wilson
-
依托单位:
COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
-
批准号:8168450
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2010
-
负责人:Patrick Christopher Wilson
-
依托单位:
The Role of Natural Human Anergic B cells in Systemic Lupus Erythematosus Patholo
-
批准号:7684353
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2009
-
负责人:Patrick Christopher Wilson
-
依托单位:
Autoimmunity Lymphocyte Repertoire Core (ALRC)
-
批准号:7688953
-
项目类别:
-
资助金额:$21.88万
-
财政年份:2009
-
负责人:Patrick Christopher Wilson
-
依托单位:
Principal Project: B cell response underlying Celiac disease antibody and autoantibody responses
-
批准号:10631980
-
项目类别:
-
资助金额:$23.62万
-
财政年份:2009
-
负责人:Patrick Christopher Wilson
-
依托单位:
Early Plasma Cells as a Source of Anthrax-Neutralizing Antibodies
-
批准号:7696156
-
项目类别:
-
资助金额:$34.6万
-
财政年份:2009
-
负责人:Patrick Christopher Wilson
-
依托单位:
Principal Project: B cell response underlying Celiac disease antibody and autoantibody responses
-
批准号:10413990
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2009
-
负责人:Patrick Christopher Wilson
-
依托单位:
Principal Project: B cell response underlying Celiac disease antibody and autoantibody responses
-
批准号:10189480
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2009
-
负责人:Patrick Christopher Wilson
-
依托单位:
The origin and consequences of receptor editing and allelic-inclusion.
-
批准号:8115033
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2008
-
负责人:Patrick Christopher Wilson
-
依托单位:
The origin and consequences of receptor editing and allelic-inclusion.
-
批准号:7900045
-
项目类别:
-
资助金额:$38.12万
-
财政年份:2008
-
负责人:Patrick Christopher Wilson
-
依托单位:
The origin and consequences of receptor editing and allelic-inclusion.
-
批准号:7353408
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:Patrick Christopher Wilson
-
依托单位:
The origin and consequences of receptor editing and allelic-inclusion.
-
批准号:7675313
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:Patrick Christopher Wilson
-
依托单位:
COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
-
批准号:7610578
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2007
-
负责人:Patrick Christopher Wilson
-
依托单位:
COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
-
批准号:7382045
-
项目类别:
-
资助金额:$26.19万
-
财政年份:2006
-
负责人:Patrick Christopher Wilson
-
依托单位:
COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
-
批准号:7171274
-
项目类别:
-
资助金额:$21.52万
-
财政年份:2005
-
负责人:Patrick Christopher Wilson
-
依托单位:
COBRE: OMRF: B CELL TOLERANCE--SECONDARY IMMUNE RESPONSE
-
批准号:7170311
-
项目类别:
-
资助金额:$11.72万
-
财政年份:2005
-
负责人:Patrick Christopher Wilson
-
依托单位:
COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
-
批准号:6981935
-
项目类别:
-
资助金额:$19.87万
-
财政年份:2004
-
负责人:Patrick Christopher Wilson
-
依托单位:
COBRE: OMRF: B CELL TOLERANCE DURING SECONDARY IMMUNE RESPONSES
-
批准号:7011748
-
项目类别:
-
资助金额:$16.69万
-
财政年份:2004
-
负责人:Patrick Christopher Wilson
-
依托单位:
海外基金